Weight Loss Drugs Like Wegvoy and Zepbound Users - Nestlé Launches $5 Pizza For You
Weight Loss Drugs Like Wegvoy and Zepbound Users - Nestlé Launches $5 Pizza For You
On Tuesday, Nestlé SA (OTC:NSRGF) (OTC:NSRGY) unveiled Vital Pursuit, a new line of foods designed to complement GLP-1 weight loss medications and aid consumers focused on weight management.
週二，雀巢公司（場外交易代碼：NSRGF）（場外交易代碼：NSRGY）推出了Vital Pursuit，這是一種新的食品系列，旨在補充 GLP-1 減肥藥物並幫助專注於體重管理的消費者。
This comes amid fears among investors that food companies could see their sales suffer significantly.
這是在投資者擔心食品公司的銷售可能會受到嚴重影響之際發生的。
Related: Changing Frugal Eating Habits – How Novo Nordisk/Eli Lilly's Weight Loss Drugs Reshaping Food Spending.
相關： 改變節儉的飲食習慣——Novo Nordisk/Eli Lilly的減肥藥物如何重塑食物支出。
The food and drink processing conglomerate says the new line includes protein, fiber, and essential nutrients, and it is portioned to accommodate the reduced appetite of weight loss medication users.
這家食品和飲料加工集團表示，新產品線包括蛋白質、纖維和必需營養素，其分配是爲了適應減肥藥物使用者食慾不振的情況。
This line also supports a balanced diet for anyone on a weight management journey, marking Nestlé's first venture into food products tailored specifically for GLP-1 users.
該系列還支持任何正在進行體重管理的人均衡飲食，這標誌着雀巢首次涉足專爲 GLP-1 用戶量身定製的食品。
GLP-1 medications significantly influence how Americans manage weight, presenting a growing market opportunity.
GLP-1 藥物極大地影響了美國人控制體重的方式，帶來了越來越大的市場機會。
Wegvoy and Ozempic (semaglutide) from Novo Nordisk A/S (NYSE:NVO) and Eli Lilly And Co's (NYSE:LLY) Zepbound and Mounjaro (tirzepatide) have garnered tremendous fame as these "miracle" drugs have been shown to be effective at helping people lose weight by suppressing appetite.
來自諾和諾德A/S（紐約證券交易所代碼：NVO）和禮來公司（紐約證券交易所代碼：LLY）Zepbound和Mounjaro（tirzepatide）的Wegvoy和Ozempic（semaglutide）廣爲人知，因爲這些 “奇蹟” 藥物已被證明可以有效通過抑制食慾來幫助人們減肥。
According to the National Center of Health Statistics, nearly half of American adults attempt weight loss annually.
根據國家衛生統計中心的數據，將近一半的美國成年人每年嘗試減肥。
Moreover, in 2023, one in 60 adults was prescribed GLP-1 medications, with projections from the American Pharmacists Association indicating a rise in 2024.
此外，在 2023 年，每 60 名成年人中就有一人服用了 GLP-1 藥物，美國藥劑師協會的預測顯示，2024 年的處方量有所增加。
J.P. Morgan Research forecasts that the number of GLP-1 users in the U.S. could reach 30 million by 2030, roughly 9% of the population.
摩根大通研究預測，到2030年，美國的 GLP-1 用戶數量可能達到3000萬，約佔人口的9％。
Tom Moe, President of Nestlé USA Meals Division, noted that Nestlé aims to expand Vital Pursuit with more product formats as the market evolves.
雀巢美國膳食部總裁湯姆·莫指出，隨着市場的發展，雀巢的目標是通過更多產品形式來擴展Vital Pursuit。
Vital Pursuit will debut in Q4 with 12 SKUs, available at select retailers nationwide.
Vital Pursuit將於第四季度首次亮相，共有12個SKU，在全國部分零售商處有售。
The product range includes frozen bowls with whole grains or protein pasta, sandwich melts, and pizzas, all priced at $4.99 and under.
產品範圍包括裝有全穀物或蛋白質意大利麪的冷凍碗、三明治和披薩，價格均在4.99美元及以下。
These products are portioned for controlled eating and include essential nutrients like protein, vitamin A, potassium, calcium, or iron. Vital Pursuit also offers gluten-free and air-fryer-ready options for added convenience.
這些產品按比例分配，可控制飲食，包括蛋白質、維生素 A、鉀、鈣或鐵等必需營養素。Vital Pursuit 還提供無麩質和即用空氣炸鍋的選項，以增加便利性。
Photo Via Shutterstock
照片來自 Shutterstock
譯文內容由第三人軟體翻譯。